Loading company
$149.98+1.3%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Past performance
- 1W
- +2.4%
- 1M
- +8.6%
- 3M
- +2.4%
- 6M
- +0.8%
- 1Y
- -54.9%
- 5Y
- -52.9%
Just reported
From Insulet's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$842M
+19% y/y
+5.0% q/q
Guided
—
No guide given
Actual
$2.03
+64% y/y
+48% q/q
Guided
—
No guide given
Actual
$189.8M
+61% y/y
+46% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Built from Insulet Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$149.98+1.3%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
The themes Insulet is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$130BA+
SYKStryker Corp.$121.3BA+
EWEdwards Lifesciences Corporation$60.8BA+
GEHCGE Healthcare Technologies Inc.$37.4BA
GKOSGlaukos Corp$14.6BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade C+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Insulet Corporation’s grade history. The other 39 go back to November 2016.
